AstraZeneca PLC Ordinary Shares (AZN)
R&D to Revenue
23.80%
Quarterly · Period ending:
AZN R&D to Revenue
Latest reported23.80%period ending
Latest reported23.80%period ending
AZN Quarterly R&D/Revenue (0.00% → 23.80%)
Latest values, visible window
High-resolution chart · PNG
AZN r&d to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 16.3211% | |
| 16.8379% | |
| 16.3028% | |
| 16.6498% | |
| 15.4368% | |
| 15.3392% | |
| 18.4899% | |
| 15.5176% | |
| 14.5085% | |
| 0% | |
| 0% | |
| 0% | |
| 11.6856% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% |